Oregon Medicaid targets expensive hepatitis drug

by Jonathan J. Cooper

(AP)—An Oregon Medicaid committee is expected to significantly scale back access to an effective—but expensive—new drug used to treat hepatitis C.

The decision on Thursday would allow only a narrow set of Medicaid patients to be treated with the $1,000-per-pill drug known as Sovaldi.

Medical experts on Oregon's pharmaceutical review committee question whether the drug is worth the . Oregon's guidelines would allow the drug to be used only for patients with later stages of who have been compliant with previous medical treatments and drug-free for at least six months. The drug could only be prescribed by a liver specialist.

Oregon is grappling with the issue a day after Illinois' Medicaid program put in place tight restrictions on the use of the drug.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Medical groups question price of new hep C drug

Mar 11, 2014

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer ...

FDA advisers unanimously back J&J hepatitis C drug

Oct 24, 2013

An experimental hepatitis C drug from Johnson & Johnson has won unanimous support from government experts who say the medication should be approved to treat patients infected with the liver-destroying virus.

Recommended for you

Merck completes sale of consumer unit to Bayer

15 hours ago

Drugmaker Merck said Wednesday that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 ...

Viagra ads target women for first time

Sep 30, 2014

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women.

User comments